Latest news with #HOYA
Yahoo
02-06-2025
- Business
- Yahoo
HOYA Vision Care Acquires Centennial Optical
Acquisition Strengthens Service to the Canadian Market MISSISSAUGA, ON, June 2, 2025 /PRNewswire/ -- HOYA Vision Care is proud to announce the acquisition of Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. The acquisition represents a significant opportunity to add to Centennial Optical's solid foundation and leverage it with HOYA's resources and technologies. The complementary capabilities of the two companies will elevate their ability to better serve the Canadian market. "We continuously seek new opportunities to deliver greater value and drive innovation," said Steven Haifawi, President of HOYA Vision Care Canada. "This strategic investment expands both our companies' capabilities and enhances our competitive positions in the market while strengthening our partnerships with customers across Canada." "We carefully considered the future of our business, our customers, and our employees," said Allen Nightingale, President of Centennial Optical. "What stood out about HOYA was more than just their industry leadership; it was their alignment with our culture, values, and mission. HOYA shares our commitment to innovation, integrity, and customer focused service, which made them the right partner for Centennial's next chapter." HOYA is committed to maintaining the high level of service and support Centennial Optical is known for, while leveraging synergies to further improve customer experience in the long-term. To learn more, visit HOYA Vision Care Canada online (English and French). About HOYA Corporation Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company, and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of over 35,000 people. For more information, please visit About HOYA Vision Care For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens industry. The company is dedicated to providing innovative vision care solutions for every stage of a patient's life. With a presence in over 50 countries, HOYA Vision Care has a leading position in myopia management category and a proven expertise in advanced lens designs, high performance photochromic technologies and high-quality AR coatings. HOYA Vision Care's solid market portfolio includes HOYA, Vision Ease, SEIKO and PENTAX optical lenses, as well as innovative products such as MiYOSMART myopia control lenses for children, Hoyalux iD MySelf individualized progressive lenses and the Sensity range of photochromic lenses. The company employs over 20,000 employees worldwide with large scale production facilities in Asia, Europe, and the US and 38 local Rx laboratories globally. For more information, please visit About Centennial Optical Founded in 1967, Centennial sells optical goods and services to Canadian Eye Care Professionals (Optometrists and Opticians), optical laboratories and optical retailers. For more information, please visit View original content to download multimedia: SOURCE HOYA Vision Care, North America Sign in to access your portfolio
Cision Canada
02-06-2025
- Business
- Cision Canada
HOYA Vision Care Acquires Centennial Optical Français
Acquisition Strengthens Service to the Canadian Market MISSISSAUGA, ON, June 2, 2025 /CNW/ -- HOYA Vision Care is proud to announce the acquisition of Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. The acquisition represents a significant opportunity to add to Centennial Optical's solid foundation and leverage it with HOYA's resources and technologies. The complementary capabilities of the two companies will elevate their ability to better serve the Canadian market. "We continuously seek new opportunities to deliver greater value and drive innovation," said Steven Haifawi, President of HOYA Vision Care Canada. "This strategic investment expands both our companies' capabilities and enhances our competitive positions in the market while strengthening our partnerships with customers across Canada." "We carefully considered the future of our business, our customers, and our employees," said Allen Nightingale, President of Centennial Optical. "What stood out about HOYA was more than just their industry leadership; it was their alignment with our culture, values, and mission. HOYA shares our commitment to innovation, integrity, and customer focused service, which made them the right partner for Centennial's next chapter." HOYA is committed to maintaining the high level of service and support Centennial Optical is known for, while leveraging synergies to further improve customer experience in the long-term. To learn more, visit HOYA Vision Care Canada online (English and French). About HOYA Corporation Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company, and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of over 35,000 people. For more information, please visit About HOYA Vision Care For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens industry. The company is dedicated to providing innovative vision care solutions for every stage of a patient's life. With a presence in over 50 countries, HOYA Vision Care has a leading position in myopia management category and a proven expertise in advanced lens designs, high performance photochromic technologies and high-quality AR coatings. HOYA Vision Care's solid market portfolio includes HOYA, Vision Ease, SEIKO and PENTAX optical lenses, as well as innovative products such as MiYOSMART myopia control lenses for children, Hoyalux iD MySelf individualized progressive lenses and the Sensity range of photochromic lenses. The company employs over 20,000 employees worldwide with large scale production facilities in Asia, Europe, and the US and 38 local Rx laboratories globally. For more information, please visit
Globe and Mail
14-04-2025
- Business
- Globe and Mail
Astigmatism Market Poised for Robust Growth in the 7MM
The Astigmatism companies in the market include - Johnson & Johnson, HOYA, Alcon, Lenstec Optical Group, HumanOptics, Carl Zeiss Meditec, Bausch + Lomb, Rayner, STAAR Surgical, EyeKon, Care Group, Morcher, Ophtec, Hanita Lenses, Omni Lens Pvt Ltd, Aurolab, SIFI, PhysIOL, and Excellent Hicare Pvt Ltd, and others. The astigmatism market is witnessing significant growth in 7MM (United States, Canada, France, Germany, Italy, Spain, and the United Kingdom), driven by a combination of demographic trends, advancements in vision correction technologies, and an increasing awareness of eye health. Key companies, including Johnson & Johnson, HOYA, Alcon, Lenstec Optical Group, HumanOptics, Carl Zeiss Meditec, Bausch + Lomb, Rayner, STAAR Surgical, EyeKon, Care Group, Morcher, Ophtec, Hanita Lenses, Omni Lens Pvt Ltd, Aurolab, SIFI, PhysIOL, and Excellent Hicare Pvt Ltd, are leading innovation in this evolving landscape. Develnsight's latest report, ' Astigmatism - Market Insight, Epidemiology And Market Forecast - 2032 ', combines robust epidemiological data with market trends, competitive landscape analysis, and assessments of the patient journey, providing valuable insights into the rapidly expanding astigmatism market. Astigmatism is a common refractive error affecting a large global population, creating a substantial demand for corrective measures and vision enhancement technologies. The astigmatism market is projected to experience steady growth in the 7MM with a robust CAGR, driven by technological advancements in vision correction methods, rising awareness about eye health, and various demographic factors such as age and genetic predisposition. While the exact genetic mechanisms are not fully understood, several studies have indicated hereditary patterns whereby astigmatism often runs in families. Download the Astigmatism market report to understand which factors are driving the Astigmatism treatment market @ Astigmatism Market Trends The astigmatism epidemiology in the DelveInsight report reveals a significant burden. Astigmatism prevalence in the general population varied from 8 to 62%, with higher rates in individuals aged 70 years or older. Furthermore, the prevalence of with-the-rule astigmatism is more significant in individuals aged 40 years or younger, while rates of against-the-rule and oblique astigmatism tend to increase with age. Gain valuable insights into the Astigmatism patient pool across the 7MM @ Astigmatism Epidemiology Analysis The report also discusses current and emerging trends in astigmatism treatment. The current treatment landscape is diverse, offering both non-invasive and surgical options tailored to the severity of the condition and patient preferences. Non-invasive treatments remain the most common approach to managing astigmatism. Prescription eyeglasses and contact lenses, particularly toric lenses, are widely utilized to correct the uneven curvature of the cornea, providing a simple and cost-effective solution for patients. Refractive surgeries such as LASIK and PRK are highly effective options. Another surgical alternative involves implanting intraocular lenses during cataract surgery or refractive lens exchange. These lenses offer long-term vision correction and especially benefit older patients undergoing cataract surgery. Orthokeratology presents a non-surgical alternative for correcting astigmatism, particularly in pediatric patients or those not yet ready for surgery, using specially designed rigid contact lenses overnight to temporarily reshape the cornea. In January 2025, the MEL 90 excimer laser by Carl Zeiss Meditec AG received U.S. FDA approval for treating myopia, hyperopia, and mixed astigmatism, marking a significant milestone in refractive surgery. Equipped with the Triple-A ablation algorithm, the MEL 90 offers highly predictable, tissue-conserving procedures and can ablate 1 diopter in just 1.3 seconds during LASIK for myopia. Emerging therapies are transforming the astigmatism treatment landscape by offering safer, minimally invasive, and highly effective alternatives to traditional surgical procedures. These innovations promise quicker recovery times and enhanced precision, addressing unmet needs in astigmatism management. Notable developments include the introduction of toric intraocular lenses (IOLs) specifically designed to correct astigmatism during cataract surgery or refractive lens exchange. Another emerging alternative is SMILE (Small Incision Lenticule Extraction), a flapless procedure utilizing femtosecond laser technology, which is particularly suitable for patients with dry eyes or thin corneas. Stay ahead with the latest breakthroughs, FDA approvals, and eco-friendly innovations shaping the future of the Astigmatism treatment landscape. Visit Astigmatism Recent Developments As these emerging treatments gain traction, they address key unmet needs in astigmatism management, such as minimizing visual disturbances and expanding eligibility for procedures. With ongoing research and development in areas like gene-editing technologies, such as CRISPR/Cas9, and regenerative medicine, such as stem cell therapy to regenerate damaged ocular tissues, the future of the astigmatism treatment market looks increasingly promising. Table of contents 1. Key Insights 2. Executive Summary of Astigmatism 3. Astigmatism Competitive Intelligence Analysis 4. Astigmatism: Market Overview at a Glance 5. Astigmatism: Disease Background and Overview 6. Patient Journey 7. Astigmatism Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Astigmatism Unmet Needs 10. Key Endpoints of Astigmatism Treatment 11. Astigmatism Marketed Products 12. Astigmatism Emerging Therapies 13. Astigmatism: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Astigmatism 17. KOL Views 18. Astigmatism Market Drivers 19. Astigmatism Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Dry Age-Related Macular Degeneration Pipeline Insight Dry Age-Related Macular Degeneration Pipeline Insight provides comprehensive insights about the Dry Age-Related Macular Degeneration pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Dry Age-Related Macular Degeneration manufacturers, including Belite Bio (NASDAQ: BLTE), Inflammx Therapeutics, Ocugen (NASDAQ: OCGN), OliX Pharmaceuticals, Gensight Biologics (NASDAQ: GNST), Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics (NASDAQ: CGTX), Aviceda Therapeutics, Galimedix Therapeutics, Mitotech (NASDAQ: MITO), Annexon, Inc. (NASDAQ: ANNX), NGM Biopharmaceuticals (NASDAQ: NGM), Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, and ONL Therapeutics, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
